Lantern Pharma (LTRN) Total Current Liabilities (2019 - 2026)

Lantern Pharma (LTRN) has reported Total Current Liabilities for 8 consecutive years, with $4.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 11.5% year-over-year to $4.3 million; the trailing twelve-month figure through Jun 2026 stood at $4.3 million (down 11.5% YoY), and the FY2025 full-year result was $4.5 million, up 3.93% from the prior year.
• Total Current Liabilities grew to $4.3 million in Q2 2026 per LTRN's latest filing, from $3.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $5.3 million in Q2 2022 and bottomed at $2.3 million in Q3 2023.
• Historically, Total Current Liabilities has averaged $3.7 million across 5 years, with a median of $3.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 362.56% in 2022, then sank 43.14% in 2023.
• Over 5 years, Total Current Liabilities stood at $2.8 million in 2022, then dropped by 4.29% to $2.7 million in 2023, then surged by 61.72% to $4.3 million in 2024, then advanced by 3.93% to $4.5 million in 2025, then retreated by 3.98% to $4.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $4.3 million, $3.8 million, and $4.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.